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Introduction
The cornea is a structure of the anterior segment of the eye 
that protects the inner ocular tissues and focuses the ex-
ternal light onto the retina. The cornea is composed of five 
distinct layers: a stratified squamous, non-keratinized, epi-
thelium; an acellular layer of collagen fibers called Bowman’s 
layer; the stroma, a regular spaced collagen fibrils forming 
the 90% of cornea’s thickness, that contains fibroblast like 
cells and nerves; a basal lamina, the Descemet’s membrane; 
and a single layer of endothelial cells. The cornea has unique 
properties being avascular, transparent and the most densely 
innervated tissue of the human body (Muller et al., 2003). 
Corneal nerves, originating from the ophthalmic branch 
of the trigeminal nerve, provide mechanical, chemical and 
thermal sensitivity and exert also a trophic supply to this 
avascular structure by releasing nutrients and trophic factors 
(Muller et al., 2003; Shaheen et al., 2014).
Several local and systemic conditions that affect the cor-
nea such as diabetes, dry eye, herpes simplex keratitis and 
neurotrophic keratitis, are associated with impairment of 
corneal innervation leading to decrease in tear production 
and impairment of wound healing (Sacchetti and Lambiase, 
2014; Mastropasqua et al., 2017). The cornea is character-
ized by peculiar properties that make it a unique tissue to be 
used as a model for regenerative medicine studies, in fact, 
the cornea can be directly visualized and corneal structures, 
including nerves may be easily evaluated for both function 
and morphology using standard instruments such as slit 
lamp and in vivo confocal microscopy (IVCM) (Cruzat et 
al., 2016). Recently, the cornea model has been successfully 
used in phase I/II clinical trials to obtain regulatory approval 
for cell therapy in limbal stem cell deficiency, a rare corneal 
disease, orphan of medical treatment. In fact, the possibility 
of a direct visualization of corneal structures, including the 
epithelium, associated with well standardized clinical safety 
and efficacy outcomes, allowed scholars to demonstrate the 
regenerative effects of epithelial stem cell transplantation 
(Rama et al., 2017). The cornea represents also a useful mod-
el to characterize neuroregeneration and to evaluate novel 
neuroregenerative therapeutic approaches in humans. 
Instruments for the assessment of corneal sensitivity have 
been developed and some of them are available for clinical 
use. Among them, the most used is the Cochet-Bonnet aes-
thesiometer, that allows scholars to easily evaluate mechan-
ical corneal sensitivity. More recently, other clinical devices 
able to assess more specific sensitivity patterns, including 
chemical, thermal and mechanical corneal sensitivity, such 
as the Belmonte’s no-contact esthesiometer, have been in-
troduced for clinical and research purposes (Belmonte et al., 
2004; Golebiowski et al., 2011).
In addition, morphology of corneal nerves can be eas-
ily evaluated and visualized by IVCM, that is a rapid and 
non-invasive imaging method (Cruzat et al., 2017). In vivo 
confocal microscopy allows scholars to visualize corneal 
nerves in health and in several ocular and systemic patho-
logic conditions and to assess their morphology in terms of 
nerve density and length, nerve branching, reflectivity and 
tortuosity (Lambiase et al., 2013; Cruzat et al., 2017) (Figure 
1). This technique has also been used to assess peripheral 
neuropathy in patients with diabetes, idiopathic small fi-
bre neuropathy, Charcot-Marie-Tooth Neuropathy Type 1 
(CMT1A), Fabry’s disease and paraneoplastic neurological 
syndromes (Cruzat et al., 2017). In addition, IVCM is used 
to evaluate in vivo the effects of treatments on corneal nerve 
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regeneration and to evaluate recovery of corneal innervation 
during pathological conditions or after surgery (Tavakoli et 
al., 2013; Cruzat et al., 2017; Culver et al., 2017; Lewis et al., 
2017). 
Recently, a neurofluorescent mouse model has been de-
veloped to study nerve regeneration in vivo. Specifically, the 
thy1-YFP transgenic mouse allows in vivo visualization of 
fluorescent sensory nerves and axonal regeneration and de-
generation can be visualized and quantified in vivo allowing 
the possibility to investigate the neurotrophic potential of 
molecules and drugs (Yu and Rosenblatt, 2007; Leckelt et al., 
2016).
Corneal Innervation Morphology and 
Function
Corneal innervation is provided by trigeminal nerve bundles 
that lose their perineurium and myelin sheaths and penetrate 
into the corneal stroma at the corneoscleral limbus, branching 
into the stromal plexus and then into the subepithelial and 
subbasal nerve plexus that provide sensitivity to the corneal 
epithelium (Muller et al., 2003). Corneal primary afferent 
neurons are represented by polymodal receptors that respond 
to mechanical, thermal and chemical stimuli, mechanore-
ceptors activated by mechanical stimuli, and cold receptors 
that respond to corneal cooling (Muller et al., 2003). Corneal 
sensory nerves react to ocular surface damage by inducing 
symptoms of pain and irritation and by eliciting protective 
reflexes such as blinking and tearing. In addition, corneal 
nerves provide trophic support to the ocular surface tissues, 
stimulate wound healing and maintain anatomic integrity by 
releasing neuromediators and growth factors (Muller et al., 
2003; Shaheen et al., 2014; Mastropasqua et al., 2017).
The corneal nerve fibers release trophic factors that war-
rant trophic support and regulatory action in the corneal 
epithelium, maintaining the physiological renewal, anatomic 
integrity and stimulating corneal wound healing (Muller et 
al., 2003). Corneal nerves express several neuromediators 
including substance P (SP), calcitonin gene-related peptide 
(CGRP), acetylcholine, cholecystokinin, noradrenaline, sero-
tonin,  neuropeptide Y (NPY), vasointestinal peptide (VIP), 
met-enkephalin, brain natriuretic peptide, vasopressin and 
neurotensin (Shaheen et al., 2014). Among them, it has been 
demonstrated that SP and CGRP are able to modulate cor-
neal epithelial cell proliferation, stratification, migration and 
adhesion (Mastropasqua et al., 2017). Specifically, it has been 
demonstrated that administration of SP associated with  in-
sulin-like growth factor-1 (IGF-1) increases corneal healing 
rate and stimulates corneal epithelial cell adhesion (Nishida 
et al., 2007). Conversely, the corneal epithelium and ker-
atocytes release neuropeptides, neurotrophins and growth 
factors that influence nerve fiber survival, differentiation, 
and maturation including nerve growth factor (NGF), brain 
derived neurotrophic factor (BDNF), ciliary neurotrophic 
factor (CNTF), neurotrophin 3, 4/5, epidermal growth factor 
(EGF), and glial cell derived neurotrophic factor (GDNF) 
(Mastropasqua et al., 2017). These mediators represent the 
main actors of the interplay between corneal epithelium 
and corneal nerve that mutually release neuromediators and 
growth factors and activate each other to produce cytokines, 
neuropeptides and neuromediators for thetrophism and 
normal healing of the cornea (Mastropasqua et al., 2017). 
The corneal epithelium produces and releases neurotrophic 
factors to support nerve trophism and healing, and corneal 
nerves produce trophic neuromediators for the survival, 
trophism and healing of the corneal epithelium (Lambiase 
et al., 1998; Muller et al., 2003; Mastropasqua et al., 2017). 
Therefore, all local and systemic conditions leading to cor-
neal sensory nerve damage can alter this interaction, causing 
an impairment of the corneal epithelium physiological re-
newal and healing rate (Mastropasqua et al., 2017).
Production and release of neuromediators during neurode-
generative diseases of the ocular surface can be easily evaluated 
by non-invasive, simple techniques such as corneal and con-
junctival impression cytology and tear sample collection, that 
allow scholars to perform biochemical and molecular evalu-
ation (Tervo et al., 1995; Yamada et al., 2000; Lambiase et al., 
2011; Sacchetti et al., 2011; Mantelli et al., 2015). Several stud-
ies using these techniques have extended results on pathogenic 
mechanisms and drug effects from animal models to human 
ocular conditions (Lee et al., 2006; Lee and Kim, 2015).
Clinical Evidence of Corneal 
Neuroregeneration 
Total or partial loss of corneal innervation leads to the devel-
opment of neurotrophic keratitis (NK). This is a rare, degen-
erative corneal disease characterized by corneal epithelium 
breakdown with scarce tendency to healing and develop-
ment of epithelial defects that may progress to corneal ulcer, 
melting and eye perforation (Mastropasqua et al., 2017). 
Several ocular and systemic diseases can damage the fifth 
cranial nerve at various levels, from the trigeminal nucleus 
to the corneal nerve endings. The most common causes of 
NK are herpetic viral keratitis, followed by trigeminal oph-
thalmic branch damage due to intracranial neoplasia and/
or neurosurgical procedures. Other ocular causes of corneal 
nerve damage include chemical burns, physical injuries, oc-
ular surgery, corneal dystrophies, and chronic topical med-
ications use. Systemic diseases, such as diabetes, multiple 
sclerosis, congenital syndromes, neurotoxic therapies and 
leprosy, can also impair corneal sensitivity, leading to NK 
(Sacchetti and Lambiase, 2014; Hsu and Modi, 2015).
Patients with NK, having a decrease of ocular surface 
sensitivity, rarely complain symptoms of ocular surface dis-
comfort, while they may refer impaired vision in most severe 
cases (Sacchetti and Lambiase, 2014). The lack of symptoms 
in NK patients should be considered in the management of 
patients with local or systemic conditions causing trigeminal 
damage, and these patients should be routinely evaluated by 
an ophthalmologist to identify signs of corneal involvement 
(Sacchetti and Lambiase, 2014). NK is classified based on the 
severity of the corneal damage in 3 stages. Stage 1 is charac-
terized by a cloudy appearance of the epithelium associated 
or not with corneal and conjunctival epithelial damage. Stage 
2 is characterized by the presence of a persistent epithelial 
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defect that may progress to corneal ulcer, perforation and/or 
stromal melting in stage 3. 
Diagnosis of NK requires a careful clinical history collec-
tion to identify risk factors for trigeminal impairment and 
a multidisciplinary approach including ophthalmologist, 
neurologist and neuro-radiologist. The ophthalmologist will 
perform a complete eye examination with the slit lamp to 
identify corneal and conjunctival signs of NK and to clas-
sify NK severity. The diagnosis of NK is confirmed by the 
presence of decreased corneal sensitivity. Corneal sensitivity 
can be qualitatively detected by touching the cornea with 
the tip of a cotton swab, while severity of corneal  sensitivity 
impairment may be quantified  by a corneal aesthesiom-
eter (Sacchetti and Lambiase, 2014). The Cochet-Bonnet 
aesthesiometer, the most frequently used, assesses corneal 
sensitivity by touching the cornea with a nylon filament: the 
length of the filament required to induce a blink reaction or 
a patient response will quantify the corneal mechanical sen-
sitivity threshold (Sacchetti and Lambiase, 2014).
Corneal nerve imaging by IVCM may also allow the in 
vivo evaluation of all corneal structures including epithelium, 
nerves, keratocytes and endothelium (Lambiase et al., 2013). In 
fact, an IVCM study demonstrated that all corneal structures 
showed changes in patients with impairment of corneal sensi-
tivity supporting the evidence of the key role of corneal nerves 
in maintaining homeostasis, survival, metabolism, and renewal 
of corneal cells (Lambiase et al., 2013) (Figure 2).
Management of NK is a challenge for ophthalmologists 
because of the lack of specific treatments able to stimulate 
corneal nerve regeneration and to restore corneal nerve 
function. Actually, NK treatment options aim at improving 
corneal healing and preventing progression of corneal dam-
age and treatments able to stimulate corneal nerve regener-
ation are highly sought-after (Sacchetti and Lambiase, 2014; 
Figure 1 A cornea of a healthy eye observed by slit lamp exam with frontal and longitudinal (insert) view. 
(A) In vivo confocal microscopy imaging shows the normal superficial corneal epithelium (B), sub-basal plexus (C), anterior stroma (D) and endo-
thelium (E).
Figure 2 Neurotrophic corneal ulcer (A) associated with impaired 
corneal innervation as demonstrated by decreased nerve density and 
increased tortuosity (B) at in vivo confocal microscopy imaging.
 A    B   
 A    B    C    D    E   
Mastropasqua et al., 2017). Currently, the use of preserva-
tive-free ocular lubricants is a first-line therapy and can be 
associated with the use of therapeutic contact lens (Lambiase 
et al., 1999; Sacchetti and Lambiase, 2014). Recently, a new 
regenerating agent, Cacicol (Laboratoires Théa, France), 
has been proposed as therapeutic option for treatment of 
persistent epithelial defects (Aifa et al., 2012; Arvola et al., 
2016). The results of a first open-label study evaluating the 
effects of Cacicol in 11 patients with refractory NK  reported 
a complete corneal healing in 73% of cases (Aifa et al., 2012). 
These data were not confirmed in a second study that de-
scribed a complete corneal healing in only 33% of 6 patients 
after 6–10 weeks of treatment (Arvola et al., 2016). Current-
ly, unresponsive cases of NK require a surgical approach 
such as tarsorraphy, amniotic membrane transplantation, or 
conjunctival flap. These approaches are effective in achieving 
corneal healing, however, they result in poor cosmetic out-
come and impairment of visual function (Chen et al., 2000; 
Hick et al., 2005; Khokhar et al., 2005; Turkoglu et al., 2014; 
Rajak et al., 2015; Uhlig et al., 2015; Ilic et al., 2016).
In the last decades, novel therapeutic approaches aiming at 
stimulating epithelial healing and/or corneal nerve regener-
ation and at restoring corneal nerve function and sensitivity 
have been proposed. Among them, several studies reported an 
high success rate in patients with NK treated with autologous 
serum eye drops, topical non-gelified platelet-rich plasma 
(PRP) eye drops, and umbilical cord serum eye drops. All these 
agents provide growth factors, neuromediators, and nutrients 
to the ocular surface and different studies reported corneal 
healing in 70% to 97% of cases (Lugo and Arentsen, 1987; Ali-
no et al., 1998; Jeng and Dupps, 2009; Geremicca et al., 2010; 
Guadilla et al., 2013; Giannaccare et al., 2015; Sanchez-Avila et 
al., 2017). Based on these encouraging results two randomized 
clinical trials (RCT) are ongoing to evaluate safety and efficacy 
of topical plasma rich in growth factors and cord blood in pa-
tients with NK (NCT03084861, NCT02707120).
The efficacy of topical treatment with thymosin beta-4 in 
patients with NK was described in an open study that re-
ported a complete corneal healing in 6 out of 9 patients. A 
RCT is currently ongoing to evaluate safety and efficacy of 
topical treatment with thymosin beta-4 in patients with NK 
at stage 2 and 3 (NCT02600429) (Dunn et al., 2010). 
In the last decades, several growth factors and neuroptp-
tides have been shown to exert a positive effect on corneal 
regeneration, including nerve growth factor (NGF), epider-
mal growth factor (EGF), SP and insulin-like growth factor-1 
(IGF-1), vascular endothelial growth factor (VEGF), sema-
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phorins, neurotrophins 3 and 4 (NT-3; NT-4), growth asso-
ciated protein-43 (Daniele et al., 1992; Muller et al., 2003; 
Nishida et al., 2007; Yanai et al., 2015). Despite encouraging 
results showed by the different trophic factors in stimulating 
corneal healing in patients with NK, very few demonstrated 
the efficacy in restoring corneal sensitivity and nerve mor-
phology as demonstrated by in vivo imaging. 
The efficacy of topical administration of a combination of 
a substance P-derived peptide, phenylalanine-glycine-leu-
cine-methionine (FGLM)-amide, with IGF-1 for the treat-
ment of persistent epithelial defects in 11 patients with NK 
was evaluated in a prospective open-label study that showed a 
complete epithelial resurfacing in 89% of cases (Nishida et al., 
2007). A larger prospective, open-label study confirmed the 
successful results showing a complete corneal healing in 73% 
of 25 patients with persistent epithelial defects associated with 
NK treated with topical FGLM-amide and IGF-1-derived 
peptide within 4 weeks of treatment (Yamada et al., 2008).
 Topical treatment with NGF also represents a promising 
strategy to induce a durable recovery of trigeminal nerve 
function. A first open-label study evaluating the efficacy of 
NGF eye drops treatment in 12 patients with neurotrophic 
keratitis at stage 2 and 3 reported complete corneal healing 
in 100% of cases after 10 days to 6 weeks treatment asso-
ciated with a recovery of corneal sensitivity in most of the 
patients (Lambiase et al., 1998). A subsequent open-label, 
non-comparative study confirmed the previous results 
showing a complete corneal healing in 45 out of 45 eyes with 
NK at stage 2 and 3 refractive to medical treatments within 
6 weeks of treatment. In this study, patients also showed 
significant improvement of corneal sensitivity, tear function 
and visual acuity (Bonini et al., 2000).
In addition, the potential effect of NGF in inducing nerve 
regeneration has been clearly demonstrated in several hu-
man diseases, such as diabetic, traumatic and toxic neuropa-
thy (Sacchetti and Lambiase, 2014). Recently, a novel recom-
binant human NGF has been developed and has successfully 
completed the clinical development phase and recently 
received marketing authorization in Europe (EU/1/17/1197) 
opening new prospective for its next clinical use for inducing 
corneal neuroregeneration (Ferrari et al., 2014).
An open study reported that treatment with oral nicergo-
line was effective in reaching a complete corneal healing in 
23 out of 27 eyes with NK and in improving corneal sensitiv-
ity. These effects were associated with a significant increase 
in tear level of NGF (Lee and Kim, 2015).
Other neurotrophic factors are under investigation. 
Specifically, topical treatment with CNTF in mice with 
wounded corneas showed an increased nerve fiber density 
8 weeks after wounding (Reichard et al., 2014). The admin-
istration of pigment epithelial-derived factor in association 
with docosahexaenoic acid after experimental surgery  in 
rabbits showed a 75% of recovery of corneal sensitivity af-
ter 7 weeks of treatment (He et al., 2015). Subconjunctival 
injection of neuropeptide FF in diabetic mice promoted 
corneal nerve injury recovery and epithelial wound heal-
ing (Dai et al., 2015).
Conclusions
The cornea represents a unique model to evaluate in vivo 
the morphology and function of sensory nerves, their role 
in maintaining tissue trophism, the crosstalk between nerves 
and cells and the effect of neuroregenerative drugs. The “hu-
man model” of the corneal disease induced by sensory nerve 
impairment is called NK. In fact, all local and systemic con-
ditions causing damage to the trigeminal nerve may decrease 
corneal sensitivity and lead to the development of NK that 
is characterized by the development of non-healing corneal 
defects associated with lack of ocular symptoms. A multi-
disciplinary approach to patients with NK will aid at early 
identifying patients with NK and at improving their clinical 
outcome. The management of NK is still a challenge, due to 
the lack of pathogenic treatments targeting nerve regenera-
tion. The development of novel molecules stimulating corne-
al nerve regeneration will improve the clinical management 
and outcomes of this disease. 
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